

# Cancer Alliance Plan 2023-24

Transforming the diagnosis, treatment and care for cancer patients in **Humber and North Yorkshire**

Workstream	Objectives	What success looks like
<h3>Faster Diagnosis and Operational Performance</h3>	<ul style="list-style-type: none"> <li>Reduce the number of patients waiting over 62 days for diagnosis and treatment</li> <li>Achieve the <b>Faster Diagnosis Standard</b> for 75% of all patients</li> <li>Meet <b>Best Practice Timed Pathway</b> milestones for 80% of patients with suspected prostate, lower gastrointestinal and breast cancer</li> <li>Achieve the <b>Faster Diagnosis Standard</b> for 75% of patients on a suspected skin cancer pathway</li> <li>Roll out <b>Teledermatology</b> in all areas of Humber and North Yorkshire</li> <li>Patients with non-specific symptoms (NSS) in all areas of Humber and North Yorkshire can be referred on to a <b>NSS pathway</b></li> </ul>	<ul style="list-style-type: none"> <li>Less than 381 patients waiting to start first treatment more than 62 days after a GP urgent suspected cancer referral</li> <li>75% of all patients referred urgently by their GP for suspected cancer will be diagnosed, or have cancer ruled out, within 28 days</li> <li>Improved operational performance and patient experience for 80% of patients with suspected prostate, lower gastrointestinal and breast cancer</li> <li>75% of all patients with suspected skin cancer will be diagnosed, or have cancer ruled out, within 28 days of referral</li> <li>An increase in high spec images accompanying suspected skin cancer referrals, leading to faster diagnosis and treatment of skin cancer</li> <li>Sustainable commissioning arrangements in place to continue service provision in 2024/25 and increased referrals into NSS pathways</li> </ul>
<h3>Early Diagnosis</h3>	<ul style="list-style-type: none"> <li>Improve early diagnosis rates for the 20% most deprived communities in <b>Humber and North Yorkshire</b></li> <li>Deliver <b>NHS Targeted Lung Health Check</b> invitation, attendance, and CT scan run rates in line with the national ambition</li> <li>Achieve 50% uptake of Lung Health Checks</li> <li>Develop clear expansion plans for the Lung Health Check service in 2024/25</li> <li>Ensure 80% of lower gastrointestinal suspected cancer referrals are accompanied by a known <b>Faecal Immunochemical Test (FIT)</b> result</li> <li>Increase the use of <b>Colon Capsule Endoscopy</b></li> <li>Test all patients with lower gastrointestinal and endometrial cancers for Lynch syndrome</li> <li>Invite more than 80% of patients with <b>cirrhosis</b> to participate in surveillance programme</li> <li>More than 60% of patients with cirrhosis to attend surveillance ultrasound</li> <li>Commission a <b>Cytosponge</b> service by March 2024</li> <li>Establish a process to identify and triage patients who are at high risk of pancreatic cancer and refer to the regional surveillance coordinator for enrolment into the <b>EUROPAC study</b></li> <li>Use the <b>PinPoint blood test</b> to optimise patient referral on suspected cancer referral pathways</li> <li>Establish and test clinical and operational processes in readiness for implementing the <b>GRAIL blood test</b></li> <li>Commission a bio sampling service for <b>GRAIL</b></li> </ul>	<ul style="list-style-type: none"> <li>More people from the 20% most deprived communities are accessing <b>primary care</b> and <b>cancer screening</b> services</li> <li>Improved staging outcomes for the 20% most deprived, with increased numbers of people being diagnosed at stage one or two</li> <li>Reduced health inequalities for the 20% most deprived</li> <li>Increased use of <b>GP Direct Access</b> for the 20% most deprived</li> <li>Increased number of Lung Health Check invitations sent to eligible patients and a higher number of checks and CT scans completed.</li> <li>50% or more <b>eligible patients</b> take up their Lung Health Check invitation</li> <li>Clear plans for the increased roll out of Lung Health Check services across Humber and North Yorkshire will be developed and ratified</li> <li>A known FIT result is included in 80% of lower gastrointestinal suspected cancer referrals and the <b>Faster Diagnosis Standard</b> is achieved.</li> <li>Increased numbers of patients receiving a diagnosis at stage one or two</li> <li>Increased number of patients using colon capsule endoscopy and a higher number of case reports uploaded to an electronic case report form.</li> <li>100% of tumours tested for Lynch syndrome</li> <li>More than 80% of patients with cirrhosis invited to take part in surveillance</li> <li>More than 60% of patients with cirrhosis attended surveillance ultrasound</li> <li>Cytosponge service commissioned and attended by patients at most risk of developing oesophageal cancer by March 2024</li> <li>An increased number of patients at high risk of pancreatic cancer are enrolled into the EUROPAC study</li> <li>Improved tools are available for clinical decision making and can support referrals into suspected cancer pathways</li> <li>Approved processes for the use of GRAIL blood test, which can detect more than 50 types of cancer before symptoms appear, are implemented by April 2024.</li> <li>A bio sampling service for GRAIL will go live in April 2024</li> </ul>
<h3>Treatment and Care</h3>	<ul style="list-style-type: none"> <li>Implement the three agreed "<b>Getting it Right First Time</b>" (GIRFT) recommendations for the lung cancer pathway</li> <li>Implement National Audit recommendations for breast, prostate, oesophageal and bowel cancer</li> <li>Offer four <b>personalised care interventions</b> to all patients diagnosed with cancer</li> <li>Collect and submit 100% of personalised care data to the <b>Cancer Outcomes Service Data (COSD)</b> set</li> <li>Fully operational <b>Personalised Stratified Follow Up</b> pathways for all eligible patients with breast, prostate, lower gastrointestinal, and endometrial cancer</li> <li>Deliver a Psychosocial Support plan</li> </ul>	<ul style="list-style-type: none"> <li>85% radical treatment rates, 20% surgical resection rates for Non-Small Cell Lung Cancer (NSCLC), and radical therapies follow up protocols approved and operational</li> <li>Reduced re-operation rates for patients with breast cancer</li> <li>Increased number of high risk / locally advanced patients with prostate cancer are considered for <b>radical treatment</b></li> <li>100% of patients with curative oesophageal cancer have <b>PET-CT scans</b></li> <li>Reduced variation in <b>neoadjuvant radiotherapy treatment</b> in patients with rectal cancer</li> <li>100% of patients diagnosed with cancer are offered end of treatment summaries, health and wellbeing support, cancer care reviews, and personalised care plans based on the results of holistic needs assessments</li> <li>100% of personalised care data collected from the four personalised care interventions and submitted to the COSD set</li> <li>Personalised Stratified Follow Up pathways for eligible patients with breast, prostate, lower gastrointestinal and endometrial cancer, are operational in all Trusts across Humber and North Yorkshire</li> <li>A plan to support people's psychological health from diagnosis of cancer is delivered</li> </ul>
<h3>Patient engagement and experience of care</h3>	<ul style="list-style-type: none"> <li>Establish a strategy and structure for co-production</li> <li>Use insight and feedback to develop and co-produce projects and new services within the programme</li> </ul>	<ul style="list-style-type: none"> <li>Published strategy and structure in operation</li> <li>Programme plans illustrative of patient engagement and co-production backed with purpose designed patient engagement plans</li> </ul>